FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs
The U.S. Food and Drug Administration (FDA) has announced new measures to make the development of biosimilar treatments faster, more efficient, and less costly. These updates simplify biosimilarity studies, reduce unnecessary clinical testing, and create clearer pathways for biosimilars to be developed as interchangeable with brand-name biologics. According to the Biosimilars Forum, these policy changes […]
Murphy Introduces Bipartisan Legislation to Protect Medicare for Physicians and Patients
In response to growing concerns over physician reimbursement cuts, Congressman Greg Murphy, M.D., has introduced the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 10073). The legislation seeks to protect access to care for Medicare beneficiaries by preventing reimbursement reductions and providing a modest inflationary adjustment for physicians. “America’s physicians are at a breaking […]
HHS Notice of Benefit and Payment Parameters for 2026 Proposed Rule
On October 10, 2024, the Centers for Medicare & Medicaid Services (CMS), in collaboration with the U.S. Department of Health and Human Services (HHS), published the Notice of Benefit and Payment Parameters (NBPP) for the 2026 Proposed Rule. This rule signals that CMS, along with the Department of Treasury and the Department of Labor (collectively […]
2024 FGS & SGNA Joint Annual Meeting Recap
This September, professionals from across the gastroenterology field gathered at the Hilton Orlando Lake Buena Vista for the 59th Annual Meeting of the Florida Gastroenterologic Society (FGS) and 48th Annual Joint Meeting of the FGS and the Society of Gastroenterology Nurses and Associates (SGNA). Over the span of three enriching days, attendees shared insights, participated […]
Spring FGS Meeting Highlight: Learn About the Path to Diagnosing Acid Sphingomyelinase Deficiency (ASMD)
Please join us to learn more about the path to diagnosing Acid SphingomyelinaseDeficiency (ASMD), presented by Dr. Kryieckos Aleck, Geneticist of the University of New Mexico. ASMD is a progressive, multisystemic genetic disease that impacts both children and adults and is historically known as Niemann-Pick disease (NPD) types A, A/B, and B. You can attend […]
Spring FGS Meeting Highlight: Unveiling STELARA® (ustekinumab) As A First Line Biologic Option with Real-World Evidence
Join us for an exclusive live educational program at the upcoming Spring FGS Meeting, featuring esteemed Gastroenterologist Dr. Ronen Arai from Digestive CARE of N. Broward, Coral Springs, FL. Dr. Arai will delve into the cutting-edge treatment STELARA® (ustekinumab), showcasing its efficacy as a first-line biologic option for adults with moderately to severely active Crohn’s […]
Non-liver-related mortality can be higher in NAFLD ‘depending on age, fibrosis stage’
A patient outcomes simulator found that non-liver-related mortality could surpass liver-related mortality in patients with nonalcoholic fatty liver disease, depending on age and fibrosis stage at diagnosis, noted data in JAMA Network Open.“NAFLD is a slowly progressive disease, therefore ongoing clinical trials evaluating NAFLD and NASH treatments use surrogate markers as primary end points,” Jagpreet […]
Q&A: Updated ACG monograph provides guidance for GI care during pregnancy, postpartum
The ACG has published a supplement to The American Journal of Gastroenterology with updated recommendations for the management of gastrointestinal disorders in patients who are pregnant or in the postpartum period.The supplement, “ACG Monograph on GI Diseases and Endoscopy in Pregnancy and Postpartum Period,” is in its third edition and was created with input from […]
HHS: Specialty drug costs up more than $300 billion since 2016
HHS has released two new reports that it said not only “illustrate the urgency of addressing skyrocketing prescription drug costs in America,” but also highlight the potential positive impact of the Inflation Reduction Act.Specifically, the reports show how inflation rebates from the Inflation Reduction Act would protect Medicare beneficiaries from increasing drug costs, according to […]
Infliximab retreatment results in remission in 35% of patients with Crohn’s disease
After previously discontinuing infliximab, 35% of patients with Crohn’s disease achieved remission at 26 weeks with drug retreatment, according to a study published in The American Journal of Gastroenterology.“Although the therapeutic arsenal of CD has increased considerably in 5 years with the availability of monoclonal antibodies targeting [interleukin-12/interleukin-23] (ustekinumab) or leukocyte trafficking (vedolizumab), the response […]